Literature DB >> 3389346

Occult carcinomas of the thyroid. Evaluation of 1,020 sequential autopsies.

W Lang1, H Borrusch, L Bauer.   

Abstract

In a sequence of 1,020 autopsies, all thyroid glands were thoroughly examined during a two-year period. Fifty-seven percent of the thyroid glands had no gross or histologic changes; approximately 22% were more or less goitrous. In 63 of 1,020 (6.2%) thyroid glands, a clinically latent carcinoma was detected. The greatest diameter of tumors measured microscopically ranged between 0.5 and 10.5 mm. Sixty-nine percent of the carcinomas were found by excision of a local change of tissue visible through close examination by the naked eye. All but one carcinoma were of papillary type, the one exception being a C-cell carcinoma. Multicentricity was found in 46% and regional lymph node metastases in 14%. There was no significant predilection of sex or age. It was concluded that these tumors have no propensity to increase to a clinically apparent thyroid disease.

Entities:  

Mesh:

Year:  1988        PMID: 3389346     DOI: 10.1093/ajcp/90.1.72

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  39 in total

1.  Total versus hemithyroidectomy for microscopic papillary thyroid cancer.

Authors:  M Gershinsky; O Barnett-Griness; N Stein; D Hirsch; G Tzvetov; O Bardicef; J Pauker; S Grozinsky-Glasberg; S Ish-Shalom; I Slutski; I Shimon; C Benbassat
Journal:  J Endocrinol Invest       Date:  2011-09-27       Impact factor: 4.256

2.  [Epidemiology, pathophysiology, guideline-adjusted diagnostics, and treatment of thyroid nodules].

Authors:  Ralf Paschke; Kurt Werner Schmid; Roland Gärtner; Klaus Mann; Henning Dralle; Christian Reiners
Journal:  Med Klin (Munich)       Date:  2010-02-20

3.  Ultrasonography in the diagnosis of cancer in multinodular goiter.

Authors:  D Barbaro; P Lapi; P Orsini; C Pasquini; F Piazza
Journal:  J Endocrinol Invest       Date:  2002-09       Impact factor: 4.256

4.  Prognosis of patients with benign thyroid diseases accompanied by incidental papillary carcinoma undetectable on preoperative imaging tests.

Authors:  Yasuhiro Ito; Takuya Higashiyama; Yuuki Takamura; Akihiro Miya; Kaoru Kobayashi; Fumio Matsuzuka; Kanji Kuma; Akira Miyauchi
Journal:  World J Surg       Date:  2007-08       Impact factor: 3.352

5.  Screening effects in risk studies of thyroid cancer after the Chernobyl accident.

Authors:  Jan Christian Kaiser; P Jacob; M Blettner; S Vavilov
Journal:  Radiat Environ Biophys       Date:  2009-02-12       Impact factor: 1.925

Review 6.  Thyroid cancer, thyroiditis and dietary iodine: a review based on the Salta, Argentina model.

Authors:  H Rubén Harach; Gustavo A Ceballos
Journal:  Endocr Pathol       Date:  2008       Impact factor: 3.943

7.  Medullary thyroid cancer, papillary thyroid microcarcinoma and Graves' disease: an unusual clinical coexistence.

Authors:  G Mazziotti; M Rotondi; G Manganella; R Franco; V Colantuoni; G Amato; C Carella
Journal:  J Endocrinol Invest       Date:  2001-12       Impact factor: 4.256

8.  Mediastinal lymph node involvement as the initial manifestation of occult thyroid cancer in the surgical treatment of lung cancer: report of a case.

Authors:  M Higashiyama; K Kodama; H Yokouchi; K Takami; K Motomura; H Inaji; H Koyama
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

9.  A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma.

Authors:  Leo A Niemeier; Haruko Kuffner Akatsu; Chi Song; Sally E Carty; Steven P Hodak; Linwah Yip; Robert L Ferris; George C Tseng; Raja R Seethala; Shane O Lebeau; Michael T Stang; Christopher Coyne; Jonas T Johnson; Andrew F Stewart; Yuri E Nikiforov
Journal:  Cancer       Date:  2011-08-31       Impact factor: 6.860

10.  Predicting the factors of lateral lymph node metastasis in papillary microcarcinoma of the thyroid in eastern China.

Authors:  Rui-chao Zeng; Quan Li; Kuai-lu Lin; Wei Zhang; Er-li Gao; Guan-li Huang; Xiao-hua Zhang; Min-hua Zheng
Journal:  Clin Transl Oncol       Date:  2012-08-08       Impact factor: 3.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.